Objective: Understanding the Lyme disease (LD) literature is challenging given the lack of consistent methodology and standardized measurement of symptoms and the impact on functioning. This prospective study incorporates well-validated measures to capture the symptom picture of individuals with early LD from time of diagnosis through 6-months post-treatment. Method: One hundred seven patients with confirmed early LD and 26 healthy controls were evaluated using standardized instruments for pain, fatigue, depressive symptoms, functional impact, and cognitive functioning. Results: Prior to antibiotic treatment, patients experience notable symptoms of fatigue and pain statistically higher than controls. After treatment, there are no group differences, suggesting that symptoms resolve and that there are no residual cognitive impairments at the level of group analysis. However, using subgroup analyses, some individuals experience persistent symptoms that lead to functional decline and these individuals can be identified immediately post-completion of standard antibiotic treatment using well-validated symptom measures. Conclusions: Overall, the findings suggest that ideally-treated early LD patients recover well and experience symptom resolution over time, though a small subgroup continue to suffer with symptoms that lead to functional decline. The authors discuss use of standardized instruments for identification of individuals who warrant further clinical follow-up.
post-antibiotic treatment symptoms (Kalish et al., 2001; Nowakowski et al., 2003) that negatively impact global life and physical functioning (Klempner et al., 2001; Shadick et al., 1999) . The Infectious Disease Society of America (IDSA) has developed a case definition of PTLDS that includes a documented episode of early or late LD with post-treatment resolution of objective signs of LD, but continuation or subsequent onset of symptoms of fatigue, widespread musculoskeletal pain, and/or complaints of cognitive difficulties. These subjective symptoms must be continuous or relapsing for at least 6 months following completion of treatment and must be severe enough to reduce the patient's functional ability (Wormser et al., 2006) .
There is some evidence based upon retrospective studies that the symptoms of PTLDS may persist for years (Asch et al., 1994; Kalish et al., 2001 ) and may negatively impact global life and physical functioning (Klempner et al., 2001; Shadick et al., 1999) . Findings from a recent prospective study of early LD showed that 45% of individuals developed fatigue, widespread pain, and/or neurocognitive complaints over a 6-month period after treatment, though only a portion of the sample had symptoms that reduced daily life functioning (Aucott, Rebman, Crowder, & Kortte, 2013) . Ten percent of the sample did meet IDSA symptom criteria for PTLDS and had greater negative impact on life functioning than the individuals that did not meet criteria for PTLDS (Aucott, Rebman, Crowder, & Kortte, 2013) . Clarification of the symptom picture over time and the relationship to possible risk factors would assist healthcare providers in better understanding this complex syndrome.
It should be noted that the over-arching concept of chronic symptoms after infection with LD (labeled PTLDS or "chronic Lyme disease") has been debated (Lantos, 2011) . Across the field of research, a standardized approach to the study of LD symptom picture has remained elusive. One of the main challenges in rectifying the LD and PTLDS literature is the underutilization of well-validated measures for symptom characterization. The majority of LD and PTLDS studies to-date have relied upon unstructured interviews to garner self-report of symptoms. Self-report has many limitations, including knowing whether one person's definition of fatigue, for example, is the same as another person's definition and whether the individual's experience of severity is the same as another person's experience. Additionally, the vast majority of the LD literature focused on symptoms is based on findings from retrospective studies, not prospective longitudinal studies. Thus, individuals are reporting symptom experiences from memory of when they began, the severity, and type, and the possible link to a tick bite. Finally, only rarely have studies of LD and PTLDS incorporated the second IDSA criteria for PTLDS-negative functional impact from the symptoms. Thus, the vast majority of the literature that has focused on PTLDS/ "chronic Lyme" has not even questioned subjects on whether the symptoms they are experiencing are leading to problems in daily life functioning. However, more recently, strides have been made to apply increased structure and rigor to the study of LD and PTLDS Aucott, Rebman, Crowder, & Kortte, 2013) . Additionally, there are scientifically-validated approaches for capturing these subjective symptom experiences, which rely upon use of structured, standardized instruments that have been shown to have the reliability and validity for the construct being measured.
The current prospective study's main aim is to use validated measures to capture the symptoms experienced by individuals with early LD from time of diagnosis through 6-month post-treatment follow-up as compared to a group of healthy controls. It is hypothesized that individuals exposed to LD will have greater fatigue, pain, and cognitive impairments as compared to healthy controls across the post-treatment follow-up period. Additionally, a secondary aim is to determine whether subgroups within the large LD cohort exist who suffer with persistent symptoms that have functional impact. Using the operationalized definition of PTLDS ; see Methods section, those who developed PTLDS will be compared to those who did not develop PTLDS and to healthy controls in regards to their symptoms of pain and fatigue. It is hypothesized that there will be a subset of approximately 10% of individuals (Aucott, Rebman, Crowder, & Kortte, 2013) who will meet full criteria for PTLDS at 6 months post-treatment. These individuals will differ in their symptom picture from individuals who do not meet criteria for PTLDS and from controls by having greater levels of pain and fatigue. Given the hypothesized very small sample size of individuals with PTLDS, the power to capture any true group differences on the neurocognitive testing is quite low and thus, conclusions of statistical significance quite limited. As such, the neurocognitive testing findings for individuals with PTLDS will be analyzed for each participant by an author (KTB) board-certified in clinical neuropsychology to determine clinical significance based upon clinical convention (2 standard deviation (SD) difference from estimated premorbid functioning based upon clinical convention, Schretlen, Testa, Winicki, Pearlson, & Gordon, 2008) .
Methods
Adults being evaluated for skin lesions and viral-like illness at an urgent care facility or primary care office in a suburban community of Baltimore, Maryland were referred to a primary care physician (JNA; primary care physician who is boardcertified in infectious diseases) beginning in the summer of 2008. Eligible participants were required to have a documented EM at time of enrollment and to have evidence of systemic disease; typically manifesting as dissemination of the primary EM lesion or concurrent onset of new flu-like or other symptoms. Enrolled participants were treatment naïve for LD and were otherwise healthy patients. Patients self-reporting during interview by research staff (prior to obtaining consent) any of the following pre-existing conditions were excluded from study participation: previous episodes of LD, chronic fatigue syndrome, fibromyalgia, cancer, autoimmune conditions, chronic hepatitis, or psychiatric condition (diagnosed episode of a major psychiatric condition). Exclusion criteria were based on the proposed IDSA (Wormser et al., 2006) case definition of PTLDS, in order to minimize the impact of medical co-morbidities linked to the common symptoms of fatigue, pain, and perceived cognitive impairment. However, cases were not excluded for more common, controlled medical conditions, including wellmanaged endocrine illness including diabetes and thyroid disease, migraine headaches, heart disease, hypertension, and menopausal status to ensure we had a more representative cohort. It is recognized that these conditions when not well-controlled can result in some of the symptoms associated with PTLDS. Additionally, subjects must have English as their first and primary language given the cognitive evaluation was conducted in English.
Study Design and Timeline
The current study is part of a larger cohort study of LD and PTLDS in which LD participants were treated with a 3-week course of oral doxycycline and followed post-treatment for a period of up to 2 years (Aucott, Rebman, Crowder, & Kortte, 2013) . The study was approved by the Johns Hopkins Medicine Institutional Review Board. The current study focused on the time period from time of diagnosis of LD (Visit 1) through 6 months post-treatment (Visit 3), including a visit 3 weeks postinitation of treatment (Visit 2). During the initial visit, at time of diagnosis (Visit 1), demographic information and medical history was recorded. At all study visits (Visits 1-3), LD participants underwent a physical exam and a clinical interview that included symptom reporting, interval medical history, medication usage, and standardized surveys. Complete blood counts (CBC), complete metabolic panels (CMP) and two-tier antibody testing for B. burgdorferi were performed as part of the initial patient clinical evaluation. All serologic testing was performed at the same commercial laboratory, and all CBC/CMP were run at an in-house laboratory. Finally, all LD participants completed neuropsychological testing to determine if there was objective evidence of cognitive impairment at Visit 2 and 3. Individuals who showed signs of treatment failure (i.e., nonresolution or development of new EM rashes or development of new onset neurologic signs, joint synovitis, or cardiac abnormalities) after a 3-week course of doxycycline were re-treated with another course of oral antibiotics. Treatment failure is known to occur in approximately 10% of cases (Wormser et al., 2006) and so is an expected outcome for a subgroup of the population. Additionally, treatment failure may be a risk factor for development of PTLDS. We wanted to ensure that we had the most representative cohort of early LD for this prospective study.
Control participants were recruited by flyer advertisement in the same primary care facilities used to recruit LD cases. Controls were screened using the same eligibility criteria as LD cases. Controls were then matched to cases based on age (+/− 3 years), sex, and presence of any of the following well-controlled medical conditions: endocrine illness including diabetes and thyroid disease, migraine headaches, heart disease, hypertension, and menopausal status. Two hundred and thirty-five control volunteers were screened for eligibility. Of those, 144 were not eligible for the study. Sixty-five were eligible for the study, but did not match any of the cases currently enrolled. Twenty-six controls were eligible and matched to an enrolled case participant. Once consented, control participants were seen for a baseline visit and then again 6 months later. At both study visits, control participants underwent a physical exam, interval medical history and medication usage interview, neuropsychological testing, and standardized surveys. Two-tier antibody testing for B. burgdorferi was done at both visits to ensure the control participants had not had exposure to LD in the interim.
Self-Report of Symptoms
LD participants' (cases) self-reported symptoms were recorded on a self-administered symptom list of 37 symptoms at the 3rd visit. Study staff inquired whether any other illnesses or life events had occurred that could contribute the reported symptoms and subjects were excluded if such illnesses or life events had occurred (see Fig. 1 ). As postinfectious symptoms have been described as waxing and waning over time, symptoms were not required to be present on the day of the study Visit 3, only that they were experienced during the prior interval.
Cases were considered to have PTLDS if they reported presence of fatigue, widespread musculoskeletal pain, or neurocognitive complaints at their 6-month study visit based upon the IDSA criteria for PTLDS (criteria 1) and based upon the definition proposed by . Fatigue was defined as self-report of new, persisting, or worsened fatigue since diagnosis. Widespread musculoskeletal pain was defined as the presence of muscle or joint pain in more than one region of the body. Neurocognitive complaints were defined as the self-reported presence of trouble focusing or concentrating, difficulty with word-finding, or difficulty with memory. Negative impact on life functioning (IDSA criteria 2) was defined by a standardized score (T) of 45 or below on the Short Form Health Survey, Version 2, composite score (SF-36; . We chose a cut-off T-score of <45, less than 0.5 SD below the normative mean, to indicate a negative impact on life functioning. Although we recognize that there will be non-clinical individuals in the general population who will naturally be below this cut-off because of other health problems, our goal is to maximize sensitivity at the expense of specificity .
Standardized Questionnaires and Testing
Pain. To capture the experience of pain in the study cohort, the short-form McGill Pain Questionnaire was employed, which divides the pain experience into sensory and affective pain, as well as provides a total pain score (Melzack, 1987) . The questionnaire includes 15 adjectives that describe a variety of pain experiences and four items that request the patient indicate the intensity of their overall pain at various times. The total score ranges from 0 to 45, while the sensory subscale score ranges from 0 to 33 and the affective subscale score ranges from 0 to 12. Higher scores indicate greater pain experiences. This instrument has been found to reliably capture the pain experience in a variety of medical populations (Chaffee, Yakuboff, & Tanabe, 2011; Lee, Harrison, Goldstein, & Brooks, 2015) . The Cronbach's alpha for the total score in the current sample is 0.91.
Fatigue impact. The Fatigue Severity Scale (FSS) (Krupp, LaRocca, Muir-Nash, & Steinberg, 1989 ) was used to measure the impact of fatigue on daily life functioning and motivation levels to engage and includes nine items that prompt the participant to indicate their level of agreement with each statement, each using a scale of 1-7, where 1 indicates strongly disagree and 7 indicates strongly agree. A total score is calculated by adding the ratings from the nine items with scores ranging from 9 to 63 with higher scores indicating greater impact of fatigue. The FSS has been found to reliably capture fatigue impact in a variety of clinical populations (Mattsson, Moller, Lundberg, Gard, & Bostrom, 2008; Valko, Bassetti, Bloch, Held, & Baumann, 2008) . The Cronbach's alpha in the current sample is 0.92 for the total score.
Cognitive functioning. A comprehensive neurocognitive battery was administered by staff trained for administering neurocognitive tests under the supervision of a board-certified clinical neuropsychologist (DJG or KTB). LD participants were tested at Visit 2 (immediate post-treatment) and Visit 3 (6 months post-treatment visit) and control subjects were tested at the initial visit and the follow-up visit 6 months later. The neurocognitive battery included the following tests: WRAT-IV (Word Reading) to measure pronounciation of English words as a measure of premorbid functioning (only administered at Visit 2; Wilkinson & Robertson, 2006) ; Digit Span subtest of the Wechsler Adult Intelligence Scale 3rd edition (Wechsler, 1997) or 4th edition (Wechsler, 2008) designed to measure basic attention and working memory; Symbol Digit Modalities Test (written version), measuring speed of information processing (Smith, 2000) ; Hopkins Verbal Learning Test-Revised, a test of verbal learning and memory (Brandt, 1991) ; and Trail-Making Test, to test attention, psychomotor speed, and cognitive flexibility (Army Individual Test Battery, 1944) . Many standard neuropsychological tests have skewed raw score distributions, and so normalized T-scores were used in all analyses for all neurocognitive tests except Digit Span. For Digit Span given that both the 3rd and 4th editions were used among subjects, a cumulative percentage was used as the standardized score for comparison among groups.
Depression. Given that clinical depression has been hypothesized to play a role in the development of PTLDS and the symptom picture overall following exposure to LD, the Beck Depression Inventory Second Edition (BDI-II; Beck, Steer, & Brown, 1996 , a well-validated instrument shown to reliably capture depressive symptomatology, Osman et al., 1997; Steer, Ball, Ranieri, & Beck, 1999 ) was administered at each visit. Each of the 21 items in the scale is rated from 0 to 3; thus, the total score represents a range from 0 to 63, with cutoffs of 0-13 ("minimal" depression), 14-19 ("mild" depression), 20-28 ("moderate" depression), and 29-63 ("severe" depression; Beck et al., 1996) . The Cronbach's alpha for the total score in this sample was 0.87. Given the overlap between the somatic symptoms of depression and the symptoms of many medical diseases, including LD and the post-treatment symptom picture, the somatic and affective subscale scores were calculated so that the relative relationships could be accounted for. There are five items that capture somatic depressive symptoms: Loss of Energy, Changes in Sleeping Patterns, Changes in Appetite, Concentration Difficulty, and Tiredness or Fatigue (Storch, Roberti, & Roth, 2004) and this subscale can range in scores from 0 to 15. The Cronbach's alpha within this sample for the somatic subscale was 0.83. The BDI-II has 16 items that capture affective depressive symptoms: Pessimism, Past Failure, Guilty Feelings, Punishment Feelings, Self-Dislike, Self-Criticalness, Suicidal Thoughts or Wishes, Worthlessness, Sadness, Loss of Pleasure, Crying, Agitation, Loss of Interest, Indecisiveness, Irritability, and Loss of Interest in Sex (Storch et al., 2004) and the subscale can range in scores from 0 to 48. The Cronbach's alpha for the affective subscale within this sample was 0.86.
Impact on life functioning. To determine the impact of these symptoms on life functioning, the Short Form Health Survey, Version 2 (SF-36) was given to LD participants and controls at each study visit. The SF-36 was designed to measure functioning in eight attributes of health: Physical Functioning, Role Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role Emotional, and Mental Health. Based on prior research , we used a composite score comprised of four of these subscales, Role Physical, Vitality, Role Emotional, and Mental Health. Raw scores are generated and then normalized to the 1998 population norms (T-scores with each 10 points representing one SD). Lower standardized scores represent a more negative impact on life functioning. The SF-36 has been shown to have high reliability and validity across a range of populations (Ware, Kosinski, & Dewey, 2000) . The Cronbach's alpha was >0.63 for all subscales included in the composite score and the alpha for the composite was 0.75.
Statistical Analyses
Data were analyzed using SAS v9.3 (Statistical Analysis System Institute, Cary, NC). The normality of each variable was assessed by the Shapiro-Wilk test. To compare the LD case cohort to controls on demographic, symptoms, and cognitive variables, t-tests were used for normally distributed continuous variables, non-parametric Wilcoxon rank sum tests were used for non-normally distributed continuous variables, and chi-squared tests were used for categorical variables. When applying the case definition of PTLDS, three groups were formed: PTLDS positive Lyme cases, PTLDS negative Lyme cases, and control participants. To analyze group differences on each symptom and take into consideration premorbid intellectual level we examined group membership using an ANCOVA and using the WRAT-IV Reading as a covariate. When comparing the three groups (PTLDS+, PTLDS−, Controls), post hoc analyses were conducted to identify group differences. The level of significance used for all analyses was p < .05.
Results
One hundred and twenty patients with confirmed early LD were recruited and enrolled in this prospective cohort study. Eleven case participants were excluded for not completing all three study visits. Two additional participants were excluded because they experienced a life event during the course of the study that could impact symptom picture, resulting in a cohort of 107 cases for the study (Fig. 1 ). There were no statistically significant differences between those retained in the study and those who were excluded from the study on any demographic variables. Descriptions of the study cohort and controls are shown in Table 1 . There were no group differences between early LD cases and controls with respect to sex, age, race, education, or exposure to prior traumatic life events. Of the 107 cases, eight cases were re-treated with antibiotics after the initial 3-week course of doxycycline because there was development of new objective findings (e.g., new neuropathy; five cases) or the EM rash did not fade after initial treatment or new rashes developed in other areas of the body (three cases). Table 2 shows a comparison of early LD cases versus controls across the three visits. At Visit 1 (pretreatment visit), LD case participants had consistently higher scores on the vast majority of symptom measures when compared to controls indicating more severe symptoms. Statistically significant differences between the two groups were seen for measures of fatigue (p = .02), sensory pain (p < .0005), affective pain (p < .0005), and total pain (p < .0005). Additionally, the two groups differed significantly for depressive symptoms with the cases reporting more depressive symptoms than the controls (p = .007). Upon closer inspection of the subscores, the difference was found for the somatic depressive symptoms (e.g., sleep disturbance, changes in appetite, energy level; p = .0008), but not for affective depressive symptoms (e.g., guilt or self-dislike). Cases also had a mean SF-36 composite score statistically significantly lower than the controls, indicating a greater negative impact of the symptoms on life functioning overall (p < .0005) and on the physical component of life functioning in particular (p < .0005), but not on the mental component of life functioning.
Characterization of Symptoms: Cases versus Controls
At Visit 2 (immediate post-treatment), cases continued to have statistically significantly greater somatic (p = .004) and total depressive symptoms (p = .02) compared to controls. Mean SF-36 composite scores remained statistically significantly lower for cases than the controls as well (p < .0005) as did the physical component of life functioning (p = .002). Of note, cases now differed statistically on their mental component of life functioning as compared to controls at Visit 2 (p = .01). While it is clear that cases endorsed more symptoms of fatigue, pain, and depressive symptoms during the pre-and immediate posttreatment visits, at the 6-month post-treatment visit, there are no statistical differences between cases and controls for any symptom, suggesting that the cases as a whole had returned to pre-infection "baseline" levels ( Table 2) . Displayed in Table 3 are findings from the group differences analyses between early LD cases and controls on the standardized neuropsychological tests that were administered at Visit 2 (immediate post-treatment) and Visit 3 (6 months posttreatment) for the cases and at both visits for the controls. Given that cases and controls differed on their WRAT-IV Reading (a test of premorbid functioning) score (t119, 2 = −3.05, p = .003), this score was used as a covariate in the analyses. It should be noted that the groups did not differ on their education level (see Table 1 ) and both groups scores were within the average range of functioning. No statistically significant group differences were found on any cognitive functioning measure at either time point. Even the range of scores, when comparing cases and controls, are strikingly similar, and all means fall within the average normative range of functioning.
Identification of a Subgroup of Cases
In order to identify if there was a subgroup of individuals that were exposed to and treated for LD who continued to experience clinically significant symptoms across the study period, two approaches were undertaken. For the first approach, cutoffs were established at Visit 2 on the standardized symptom measures to compare those above the cutoffs (high symptoms) with those below the cutoffs (low symptoms) on the impact on life functioning (SF-36 composite score) at Vist 2, immediately post-treatment and at Visit 3, 6 months post-treatment (the field-endorsed time point for individuals to be defined as chronic impact from LD symptoms). It is recognized that the cutoffs do not represent a true dichotomy of the symptom picture, but rather this approach was taken to investigate whether the measures are useful in distinguishing potential subgroups of individuals with early LD which might prove to be clinically useful. The cutoffs were chosen by reviewing existing literature for the study instruments and selecting a score that is deemed to reflect clinically significant levels of that symptom. For the FSS, a cut-off of 36 or greater was chosen to indicate "high fatigue symptoms" (Krupp et al., 1989) . Given healthy control scores in the current study and others (Duschek et al., 2012; Reyes Del Paso, Garrido, Pulgar, Martin-Vazquez, & Duschek, 2010) , a score of greater than 3 on the McGill Pain Scale was chosen to indicate "high pain symptoms." For the Beck Depression Inventory, a total score of 13 or greater was used as indicating clinically significant symptoms of depression (Beck et al., 1996) . As summarized in Table 4 , at both Visit 2 (immediate post-treatment) and Visit 3 (6 months post-treatment), there is a statistically significant difference in life functioning (SF-36 total score) between cases who had high symptoms (fatigue, pain, depression) at Visit 2 versus those with low symptoms. Thus by the end of standard antibiotic treatment (Visit 2), those with high (clinically significant) symptoms of fatigue, pain, or depression continue to have impact on life functioning up to 6 months later. The second approach to determining if subgroups within the cases exist was to apply the IDSA criteria definition for PTLDS Wormser et al., 2006) to identify individuals who are PTLDS+ (meet criteria at 6 months post-treatment) versus cases that are PTLDS− (do not meet criteria at 6 months post-treatment). In a way, the analyses would be used to verify that those who meet criteria based upon their self-report of symptoms differ from those who did not meet PTLDS criteria on the level of pain, fatigue, or cognitive functioning using standardized instruments. Applying the criteria resulted in a subgroup of six cases in the PTLDS+ group (or 5.6% of the sample) and 101 individuals in the PTLDS− group. Of the six PTLDS+ cases, two required retreatment following initial course of doxycycline (one had new objective finding and one had non-fading EM rash). Of the 101 PTLDS− cases, six individuals required retreatment (four developed Significance level compared to controls: *p < .05; **p < .005; ***p < .0005. new objective findings; two had non-fading EM rash or new disseminated rash). As summarized in Table 5 , at Visit 1 (time of diagnosis, pretreatment), both the PTLDS+ and PTLDS− groups differed from controls on symptoms of fatigue, pain (total, sensory, affective), and depressive symptoms (total and somatic). There was a trend toward the PTLDS+ group differing from the PTLDS− group and controls for affective depressive symptoms.
At Visit 2 (immediate post-treatment), the PTLDS+ group differed from controls on symptoms of pain (total, sensory, and affective) and depressive symptoms (total, somatic, and affective) and a trend for them differing from the other two groups on fatigue. At Visit 2, the PTLDS− group did not differ from controls on any symptoms. The same pattern was true at Visit 3 (6 months post-treatment), with the PTLDS+ group differing significantly from the controls on all symptom measures, but the PTLDS− group not differing from controls.
Of the individuals who met criteria for PTLDS (n = 6), a review of their symptom and cognitive data for indication for clinically significant findings was undertaken by the first author (KTB, a board-certified clinical neuropsychologist). Using the high-low cutoffs for each symptom measure (Table 4) , all six individuals who met criteria for PTLDS were in the high group for fatigue and/or pain at Visit 2. Of note, at Visit 3, all individuals in the PTLDS+ group were above clinical cut-off for pain, three were above clinical cut-off for fatigue, and three were above clinical cut-off for depression.
Within the PTLDS+ group, four individuals self-reported experiencing at least moderate cognitive decline in attention, memory, and/or word-finding persisting to Visit 3 (6 months post-treatment). However, none of the individuals performed below the average range on any of the cognitive instruments. In comparison to each subject's estimated "pre-morbid" intellect (WRAT-IV Reading score), none of the six individuals had any impairments or relative weakness in cognitive functioning. Of note, the four individuals who self-reported decline in cognitive functioning also had notable symptoms of pain and/or fatigue. In other words, these four individuals' experiences of cognitive decline was within the context of also experiencing clinically significant symptoms of fatigue and/or pain.
Discussion
The aim of this study was to characterize the symptoms of patients with well-defined, ideally treated, early LD using standardized, validated measures across a 6-month period. The findings support that individuals with confirmed early LD, prior to treatment with standard antibiotic therapy, experience notable symptoms of fatigue, pain, and depressive symptoms at a level statistically different from healthy controls. After treatment is complete, there are no group differences between cases and controls, suggesting that the symptoms have resolved across the group. However, knowing that individual variations can exist within a heterogeneous group, the possibility that there was a subgroup of individuals who were experiencing notable and clinically significant persistent post-treatment symptoms of pain, fatigue, depressive symptoms was investigated.
Subgroup Analyses
The first approach to capturing potential subgroup variability was to use clinically meaningful cutoffs for the various symptom measures, creating a high symptom group and a low symptom group for pain, fatigue, and depressive symptoms. The two groups (high symptom vs. low symptom) were compared on their life functioning (SF-36) in order to determine whether each symptom had a notable functional impact at Visit 2 (immediately post-treatment) and Visit 3 (6 months post-treatment). The results showed that using established cut-off scores for clinically significant symptoms present at Visit 2 can distinguish between individuals who have negative impact on daily life functioning at Visit 2, but also 6 months later at Visit 3. These findings suggest that these cut-off scores can be used to identify individuals who will likely have functional impact persisting across time and may benefit from early intervention for their post-treatment symptoms.
The second approach to investigating potential subgroup variability was to apply the IDSA criteria for PTLDS and determine if those meeting criteria differed in their symptom presentation and cognitive functioning from those who did not meet criteria. It should be noted that only six subjects met criteria, yielding a very small sample size. The results are viewed as very preliminary given the capitalization on chance variations of this small group of individuals. With that said, there are some interesting preliminary findings. Prior to treatment, but at presentation for diagnosis and initiation of care (Visit 1), the PTLDS+ group and the PTLDS− group both presented with symptoms of fatigue, pain, and depressive symptoms that were statistically significantly greater than the control group without LD. By 3 weeks post initiation of treatment (Visit 2), the PTLDS− group no longer differed from controls on pain, fatigue, or depressive symptoms suggesting that their symptoms had resolved. However, the PTLDS+ group continued to endorse greater symptoms of fatigue, pain, and depression in comparison to controls on standardized instruments at Visit 2 and this pattern held at the 6 months post-treatment visit (Visit 3). Of particular note is that all of the individuals in the PTLDS+ group were also in the "high symptom" groups for pain and/or fatigue at Visit 2. Together these findings suggest (1) that a definition of PTLDS that is based on patient reported symptoms does identify a group of patients who also has a greater level of symptoms when measured using validated questionaires, and (2) that using clinically meaningful cut-off scores of pain and fatigue immediately post-treatment (1 month post diagnosis) can identify individuals who will later meet criteria for PTLDS at 6 months.
The Role of Depression
One hypothesis in the literature is that depression is a "driver" for PTLDS. In the current study, 5 of the 107 subjects were above cut-off indicating at least mild depressive symptomatology by Visit 2 (immediately post-treatment). Of note, the individuals in this high depressive symptoms group are almost two SDs lower in their daily life functioning as compared to those below cut-off for clinically significant depressive symptoms. Of those five individuals, only two of them later met criteria for PTLDS. Thus, depression does not appear to be the sole source of functional decline in the PTLDS subgroup or for persistent symptoms for any individuals.
Cognitive Decline
In contrast to the stated hypothesis, no statistically significant differences were found between cases and controls on any objective measures of cognitive functioning after completion of treatment and all group means were solidly in the average range of functioning. As was the case with the entire cohort, the current findings do not suggest that there are cognitive impairments in the subgroup of PTLDS+ individuals, though these individuals subjectively report greater cognitive problems. The PTLDS+ group performed within the average normative range of functioning across measures. Clinical analysis of each of the six individual's cognitive testing profile revealed no clinically significant patterns of cognitive impairments either.
The current study suggests that in this ideally-treated sample of individuals with early LD there is no objective evidence of cognitive impairment. However, it should be recognized that this study included a limited number of measures of cognitive functioning. It may be that instruments that capture other domains of cognitive functioning (e.g., visual-spatial processing) may detect deficits. The instruments included in the current study were chosen as they are known to capture more global processing and integration and retrieval of information. These more global cognitive processes are typically affected by encephalitis and meningitis that have a more global impact on the brain rather than causing focal impairment per se. Evidence of encephalitis or meningitis with North American LD is rather rare (as opposed to European LD, Marques, 2015) ; but this is the only evidence of a brain-based pathological process associated with this disease (Marques, 2015; Steere, Schoen, & Taylor, 1987) .
The finding that there is no objective evidence of cognitive impairment in individuals with early LD is important as it suggests that in ideally-treated individuals, the disease process does not negatively affect brain functioning, in so much as to lead to objective cognitive dysfunction. In comparison, other studies provide evidence of statistically significant differences between individuals with "chronic Lyme disease" and controls on measures of cognitive functioning (Keilp et al., 2006; Pollina, Sliwinski, Squires, & Krupp, 1999; Shadick et al., 1999) . It should be noted that in these studies, the vast majority of differences are not clinically meaningful between the groups, and both groups are typically performing across indices solidly within the average range suggesting that no significant impairment is present. One exception is the finding of reduced processing speed between individuals with chronic LD and controls, which warrants further investigation (Keilp et al., 2006) . It may be these individuals are distracted by their pain, fatigue, and/or depressive symptoms leading them to perform more slowly on cognitive tasks. However, in our study, individuals with early LD did not differ from controls on a processing speed measure. It also should be noted that in none of the above studies was validity testing included in the battery and so there is no objective evidence (nor any comment by the authors of any of these studies) that the subjects provided a credible performance.
Also of note, depression severity was statistically significantly (though modestly) related to processing speed in the study by Keilp and colleagues (2006) , whereas other studies have not found there to be a relationship between depressive symptoms and the evidence of cognitive decline (Shadick et al., 1999) . However, Kaplan and colleagues (1992) did find evidence that depressive symptoms were related to the "perception" of cognitive decline. There is some evidence to suggest that the subjective experience of cognitive decline is associated with higher levels of pain and depressive symptoms in individuals with "chronic Lyme disease" (Kaplan et al., 2003) . In the current study, three individuals in the PTLDS+ sub-cohort met criteria for clinically significant depressive symptoms at Visit 3 and four of the six reported experiencing cognitive decline within the context of clinically significant symptoms of pain and/or fatigue. However, as noted above, none of these individuals had any evidence of significant cognitive impairment (or even relative weaknesses) in the cognitive domains assessed, including processing speed.
The current findings and past literature do not provide full explanation nor negate in any way the subjective experience of cognitive inefficiency that many individuals report. As noted above, there is some evidence to suggest that the subjective experience of cognitive decline is related to greater pain and depressive symptoms (Kaplan et al., 2003; Shadick et al., 1999) . It may be the subjective experience of cognitive decline may be a true inattention problem rooted in the distractibility components of pain and other symptoms, although such a finding was not supported by the present study. There is evidence that pain, fatigue, and depressive symptoms can interfere with efficient cognitive processing such that no brain-based impairments in cognitive functioning are present, but the distraction element of pain, fatigue, and depressive symptoms leads to inattention problems (Cockshell & Mathias, 2014) . Inattention in turn leads the individual to not efficiently and effectively process information in their daily lives leading to the subjective experience of memory decline. Further research is needed to study the relationship among the objective evidence of cognitive decline, the subjective experience of cognitive decline, the symptom profile of pain and fatigue, and the impact on daily life functioning. There also needs to be consideration that at times, individuals may not perform their best on neurocognitive tests because they want to ensure that their experience of problems is captured or because other motivations for not performing well are at play. Future research needs to delve deeper into the relationship between the subjective experience of cognitive decline and the potential factors that could be leading to that experience. There needs to be full consideration that these factors could include (1) true, frank cognitive decline, (2) other symptoms of pain, fatigue, emotional distress that may interfere with optimal cognitive processing, and (3) individuals are not providing their full effort during neurocognitive exams. Regardless of what factor(s) are playing a role, identification of the factors will assist us in designing appropriate intervention regimens because these individuals warrant clinical attention and assistance in managing their symptoms and improving their life functioning.
Study Limitations
The current findings provide a snapshot of the symptom presentation over the early recovery period for individuals with history of LD who were ideally treated and may not represent the breadth of patients with LD in the North American population. As such, it will be challenging to extrapolate the implications of these findings to the larger group of individuals who do not receive ideal treatment. However, our cohort afforded the opportunity to test a standardized evaluation approach to capture symptoms across time in order to well characterize the sample as a starting point for understanding prospective symptom presentation. From here, the standardized approach can be applied to the more heterogeneous population that have been exposed to LD and diagnosed and treated at different stages of the infection.
Although the current study extended the examination to subgroup analyses by applying the IDSA criteria for PTLDS, this resulted in a very small sample size of six individuals. As such, some statistical tests may have not had sufficient power to detect differences that were truly present. It will be important that the current findings be replicated in a larger sample to determine if the pattern of symptoms holds in a larger cohort study. We also had a rather small control group and a sample of convenience, which limited the power of the study to evaluate the differences between the groups and the generalizability of the findings to the more general population. Future research needs to incorporate a much more substantial control group that allows for fuller evaluation of the hypotheses. Conducting a power analysis during study design would assist in making a determination of the size of the control group needed.
Implications
This is the first study to use standardized measures to capture the symptom picture in a cohort of individuals prospectively defined with the EM of early LD who are ideally treated. The findings provide an overall endorsement that as a group, ideally-treated individuals recover well and experience symptom resolution over time. However, it is clear that there are some individuals, albeit a small group, who continue to suffer with symptoms that lead to functional decline. The current findings provide a clinically useful approach of using standardized instruments at 3 weeks post diagnosis (immediately post completion of standard antibiotic treatment) to identify individuals (1) with clinically significant symptoms and (2) who may have persistence of symptoms with functional impact across time. Thus, clinicians would have a way of identifying early those at risk and would not have to wait until the 6-month point to determine which patients develop functional decline before initiating referral for intervention. Much more work needs to be done to establish clinical guidelines for identifying individuals with problematic symptoms after exposure to LD, but the current findings serve as a starting point for clinicians to use standardized instruments to identify individuals who may benefit from pharmacologic treatment or behavioral interventions for symptom management. Again, further research is needed to establish the true predictive value of these cut-off scores, but at least this is a starting point for clinicians who currently have no tools for determining which patients are at risk for development of problematic symptoms and functional decline.
The current findings suggest that cognitive decline is not a problem in ideally-treated individuals with LD. Thus, clinicians can take a three-tiered approach to patients that report persistent cognitive issues. First they can reassure them that there is little evidence to suggest that frank cognitive impairments occur in ideally-treated individuals and that some of their other symptoms, such as pain and fatigue are likely impacting their ability to focus and process. Second, patients with symptoms of pain, fatigue, and depression on standardized instruments can be referred for appropriate behavioral and medicinal interventions to reduce the impact of these symptoms on daily life functioning. Finally, if there is sufficient concern after education and interventions have been applied, then patients can be referred for neuropsychological evaluation.
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